HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference

Stock News

Oct 02

HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.

The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1155672705"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155672705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155672705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155672705","market":"hk","top_or_hot":-1,"title":"HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference","media":"Stock News","content":"<p>HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.</p>\n<p>The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-02 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.</p>\n<p>The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1155672705","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155672705","pubTimestamp":1759363822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00013":"和黄医药","BK4531":"中概回港概念","BK4007":"制药","BK4588":"碎股","BK1588":"回港中概股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1587":"次新股","HCM":"和黄医药"},"translate_title":"和黄医药(00013)将在2025年欧洲肿瘤内科学会(ESMO)年会上展示临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.\nThe registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}